The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score-Reference-Cited by-同舟云学术

The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score

Published:2018-07 Issue:1 Volume:74 Page:17-23
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Miller Kurt,Carles Joan,Gschwend Jürgen E.,Van Poppel Hendrik,Diels Joris,Brookman-May Sabine D.

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer;Aziz;Expert Rev Anticancer Ther,2015

2. The changing therapeutic landscape of castration-resistant prostate cancer;Yap;Nat Rev Clin Oncol,2011

3. Public statement. Provenge: withdrawal of the marketing authorisation in the European Union;European Medicines Agency,2015

4. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer;Halabi;J Clin Oncol,2014

5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

2. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer;JAMA Network Open;2024-07-09

3. Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer;BMJ Open;2024-07

4. A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer;ESMO Open;2024-06

5. HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1;Journal of Translational Medicine;2024-02-18